The patient, a 19-year-old university student who has asked to remain anonymous, had a sample of testicular tissue removed and cryopreserved in 2023, before he underwent a bone marrow transplant to treat a serious blood disorder. Bone marrow transplantation requires high-dose chemotherapy, a regimen that can permanently destroy the spermatogonial stem cells responsible for sperm production throughout adult life. Three years after completing his treatment, clinical tests confirmed that no sperm were present in his semen, a finding that would previously have left him with no options at all.

In August 2026, surgeons reimplanted small pieces of his preserved tissue in the hope that the stored stem cells would recolonise the testis and resume spermatogenesis, the complex biological process by which sperm cells mature. The young man has recovered well and will now be monitored closely. After eight months, a sample of the transplanted tissue will be surgically removed and examined under the microscope to determine whether sperm have actually been produced. That checkpoint will provide the first concrete evidence of whether the procedure has worked in a UK patient.

The scientific logic behind the approach rests on the biology of the testis itself. Within the seminiferous tubules, spermatogonial stem cells divide and differentiate from puberty onwards, generating the successive generations of cells that ultimately become mature sperm. Chemotherapy agents and radiotherapy are highly toxic to these rapidly dividing lineages, and in prepubertal boys the tissue has not yet begun producing sperm at all. Freezing small fragments of tissue before treatment therefore preserves the only cells capable of restarting sperm production later in life, even though the tissue at the time of storage is biologically immature.

This is precisely why the technique matters for a group that existing medicine cannot serve. Semen cryopreservation is a well-established fertility preservation option for adolescent and adult males, who can simply bank a sperm sample before starting treatment. Prepubertal boys, however, do not yet produce sperm, so there has been no established clinical method to restore their fertility after sterilising therapies. More than 1,200 patients in the UK and around 3,100 worldwide have now had testicular tissue stored for potential future clinical use, creating a growing cohort of young people who may one day return to clinics like the one in Edinburgh hoping to use it.

The Edinburgh testicular project, established in 2015 with funding from the charity Children with Cancer UK, has grown over ten years into a national programme for tissue banking and translational research. In 2024 the charity provided further funding specifically to support the transplantation study that made the August 2026 operation possible. The programme’s design reflects a deliberately cautious, evidence-first strategy: tissue is collected and frozen under rigorous clinical protocols, while the transplantation step is evaluated as a research procedure before it can be offered as routine care.

Crucially, the Edinburgh team did not move into human transplantation without prior animal evidence. Studies in non-human primates demonstrated that testicular tissue frozen before sterilising chemotherapy could be transplanted back successfully, with the grafts producing mature sperm that were subsequently used in assisted reproduction to achieve a live birth. That result provided the proof of principle that cryopreserved immature tissue retains its developmental potential after thawing and reimplantation, and that the resulting sperm can lead to a healthy offspring. The primate work also helped define the surgical and biological parameters, such as graft placement and the time needed for blood vessels to regrow into the transplanted tissue and support maturation of the stem cells.

The first demonstration in a human patient came earlier this year in Belgium, where testicular tissue frozen before puberty was successfully transplanted back and subsequently produced mature sperm. That landmark result confirmed that the animal findings could be translated into people, and it set the stage for the Edinburgh procedure as the second reported worldwide. The Belgian case involved tissue preserved in childhood, while the UK patient had tissue stored as an older adolescent, illustrating that the technique may eventually serve a broad age range of patients whose fertility is threatened by treatment.

Study lead Rod Mitchell, Professor of Developmental Endocrinology at the University of Edinburgh’s Institute for Regeneration and Repair and Consultant Paediatric Endocrinologist at NHS Lothian, described the operation as a major advance. He noted that ten years ago the team began freezing and storing pieces of testicular tissue from boys before they started chemotherapy, and that some of those young men are now returning to explore their fertility options. Tracey Gillies, Medical Director at NHS Lothian, called the procedure a landmark step for young people whose future fertility may be compromised by the treatment they need to overcome serious illness, highlighting the collaboration between NHS clinicians and university researchers as an example of world-leading clinical work.

For the patient himself, the procedure carries a significance that extends beyond the laboratory. In a statement, he said that fertility was something he had struggled with personally for a long time, and that he had slowly begun to accept he might never have children of his own. He described the operation as giving him genuine hope for the future, acknowledging that no one yet knows whether it will work but emphasising that even the possibility means more than he can put into words. He also expressed the hope that taking part in the research will help other young people in the same position one day share that hope. Whether the transplanted tissue produces sperm will become clear at the eight-month examination, and even a positive result would likely still require assisted reproduction rather than natural conception. But the procedure has already established a UK-first clinical pathway, and if the Edinburgh team’s careful decade of groundwork pays off, thousands of stored tissue samples around the world could one day offer the same possibility to survivors of childhood and adolescent illness.

Subject of Research: Transplantation of cryopreserved testicular tissue to restore fertility after sterilising cancer treatment

Article Title: UK first as frozen testicular tissue transplanted to help restore fertility

Article References: UK first as frozen testicular tissue transplanted to help restore fertility. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: testicular tissue transplantation, fertility preservation, spermatogonial stem cells, chemotherapy, cryopreservation, University of Edinburgh, NHS Lothian, pediatric oncology, male infertility, bone marrow transplant, assisted reproduction, clinical trial

The research team, led by Ewa Karakulska-Prystupiuk and colleagues in Warsaw, analyzed 341 patients who received allogeneic stem cell transplants between 2014 and 2023. For each patient, the investigators recorded the lowest vitamin B12 and folate levels measured within two years after the transplant, applying deficiency thresholds derived from the NHANES population surveys. The results were striking: 49 percent of patients showed reduced vitamin B12 levels below 300 pg/mL, with 17 percent falling below 200 pg/mL, and folate deficiency, defined as a level under 3 ng/mL, affected 46 percent of the cohort.

Graft-versus-host disease occurs when donor immune cells recognize the recipient’s tissues as foreign and mount an attack. When this process becomes chronic and involves the gastrointestinal tract, the lining of the gut—the very tissue responsible for absorbing nutrients—is inflamed and damaged. The Polish team hypothesized that this mucosal injury, combined with reduced dietary intake and the effects of immunosuppressive drugs, would translate into measurable vitamin depletion, particularly for B12 and folate, both of which are absorbed through intestinal mechanisms vulnerable to inflammatory damage.

To test this, the investigators carved out a subgroup of 68 patients with confirmed chronic graft-versus-host disease, whose median age was 45.5 years. Among them, 42 had gastrointestinal involvement. When the researchers compared median vitamin levels between the two groups, the difference was unequivocal. Patients with gastrointestinal chronic graft-versus-host disease had a median vitamin B12 level of 258 pg/mL, versus 442 pg/mL in patients whose chronic disease spared the gut. Deficiency was documented in 88.6 percent of the gastrointestinal group, compared with just 11.4 percent of the others, a difference that reached high statistical significance with a p value below 0.001.

Perhaps even more telling was the dose-response relationship. The researchers found an inverse correlation between the severity of gastrointestinal graft-versus-host disease and vitamin B12 concentrations: the worse the gut involvement, the lower the circulating B12. This gradient supports a mechanistic interpretation in which progressive mucosal destruction progressively impairs the absorption machinery—including the ileal uptake pathway that normally captures vitamin B12 bound to intrinsic factor—rather than the deficiency arising from a single binary event.

Folate, the other B vitamin central to red blood cell production and DNA synthesis, followed a similar directional pattern. Levels were lower in the gastrointestinal group, consistent with the idea that an inflamed gut absorbs less of this nutrient as well, but the difference did not reach statistical significance. The authors suggest this may reflect folate’s more diffuse absorption along the small intestine, or the confounding influence of supplementation practices, though the precise explanation remains a question for future work.

The study then turned to anemia, one of the most persistent quality-of-life problems after transplantation. At 12 months post-transplant, hemoglobin concentrations were significantly lower in patients with gastrointestinal chronic graft-versus-host disease, 12.2 g/dL versus 13.25 g/dL in those without gut involvement, with a p value of 0.006. Since both vitamin B12 and folate deficiencies classically cause macrocytic anemia—oversized, underperforming red cells—one might expect the vitamin deficits to explain the anemia. They did not. Macrocytic anemia predominated in both patient groups, but it was not associated with the vitamin deficiencies, indicating that the red cell failure after transplantation stems from multiple converging causes rather than a single nutrient shortfall.

This dissociation is arguably the study’s most instructive result. Post-transplant anemia can arise from ongoing inflammatory suppression of the bone marrow, iron dysregulation, renal dysfunction, medications, and the residual effects of the conditioning regimen itself. The Warsaw data suggest that clinicians cannot assume that correcting B12 or folate levels will resolve anemia in these patients, and conversely, that a normal blood film does not rule out dangerous vitamin depletion. The two problems run on separate tracks, and each demands its own surveillance.

The practical implications are considerable. Vitamin B12 deficiency is not a benign laboratory curiosity; untreated, it can produce neurological injury, cognitive impairment, and worsening fatigue in a population already burdened by treatment toxicities. Given that roughly nine in ten patients with gastrointestinal chronic graft-versus-host disease in this cohort were deficient, the authors’ findings argue for routine, periodic measurement of B12 and folate in this subgroup, with a low threshold for supplementation even in the absence of anemia. Whether prophylactic supplementation should extend to all transplant recipients remains an open question the retrospective design cannot answer.

The study does carry the inherent limits of a single-center retrospective analysis, and vitamin levels were defined by the lowest recorded value rather than serial trends, which may capture transient dips. Still, the size of the cohort, the uniform threshold definitions, and the striking statistical separation between patient groups give the findings weight. As survival after allogeneic stem cell transplantation continues to improve, attention is steadily shifting from survival alone to the long-term functional health of survivors. Identifying a preventable, treatable deficiency affecting nearly half of all recipients—and nearly all of those with gut-directed graft-versus-host disease—is a concrete step in that direction, one that could translate into simple blood tests and inexpensive supplements protecting patients from an entirely avoidable secondary burden.

Subject of Research: Vitamin B12 and folate deficiency after allogeneic hematopoietic stem cell transplantation and its link to gastrointestinal chronic graft-versus-host disease and anemia.

Article Title: Vitamin B12 and folate deficiencies after allo-HSCT: association with gastrointestinal chronic graft-versus-host disease and anemia

Article References: Karakulska-Prystupiuk, E., Kumorek, A., Tomaszewska, A., Kacprzyk, P., Biliński, J., Jędrzejczak, W. W., & Basak, G. W. (2026). Vitamin B12 and folate deficiencies after allo-HSCT: association with gastrointestinal chronic graft-versus-host disease and anemia. Annals of Hematology. https://doi.org/10.1007/s00277-026-07276-7

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07276-7

Keywords: allogeneic stem cell transplantation, vitamin B12 deficiency, folate deficiency, graft-versus-host disease, gastrointestinal GvHD, anemia, macrocytic anemia, hematology, bone marrow transplant, post-transplant care, malnutrition, Annals of Hematology